Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313182 · ClinicalTrials.gov registry record · Phase 4
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin
A Phase 4 study, sponsored by Solventum US.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,874
- Enrollment target
NCT01313182 is a Phase 4 study that has completed, run by Solventum US. The registered enrollment target is 1,874 participants.
The verdict
NCT01313182, a Phase 4 study, has completed, sponsored by Solventum US.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,874 participants
- Enrollment target
Study Summary
We hypothesize the application of mupirocin or povidone-iodine to the nares is equally effective in short term Staphylococcus aureus(SA)suppression. Our overall study objective is to measure the rate of deep and superficial Surgical Site Infections (SSIs) after primary hip, knee, shoulder and elbow arthroplasty surgery and primary spinal fusion surgery requiring implantation of prosthetic material, when the patient receives either nasal mupirocin or nasal povidone-iodine prior to surgery. Secondary study objectives include: 1. Measure hospital length of stay and re-admission rates in the mupirocin and povidone-iodine groups. 2. Measure adverse events related to mupirocin and povidone-iodine. 3. Measure rate of SA resistance to mupirocin.
Interventions
- DRUG mupirocin calcium ointment, 2%
- DRUG 3M Skin and Nasal Antiseptic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,874 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313182
The ClinicalTrials.gov registry entry for NCT01313182 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,874 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solventum US, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mupirocin calcium ointment, 2% is the first listed.
NCT01313182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313182 about?
NCT01313182 is a clinical study titled "Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin". We hypothesize the application of mupirocin or povidone-iodine to the nares is equally effective in short term Staphylococcus aureus(SA)suppression. Our overall study objective is to measure the rate of deep and superficial Surgical Site Infections (SSIs) after primary hip, knee, shoulder and elbow ...
What is the current status of trial NCT01313182?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,874 participants. The study started on 2011-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01313182?
The interventions under investigation include: mupirocin calcium ointment, 2% (DRUG), 3M Skin and Nasal Antiseptic (DRUG).
Who is sponsoring clinical trial NCT01313182?
This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.